Share on StockTwits

GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “buy” rating reiterated by stock analysts at Galvan Research in a report issued on Monday.

Other equities research analysts have also recently issued reports about the stock. Analysts at Mainfirst downgraded shares of GlaxoSmithKline plc to an “underperform” rating in a research note on Monday, July 28th. Separately, analysts at Bank of America downgraded shares of GlaxoSmithKline plc from a “buy” rating to a “neutral” rating in a research note on Monday, July 28th. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 25th. Four equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $51.50.

Shares of GlaxoSmithKline plc (NYSE:GSK) traded up 1.04% on Monday, hitting $48.53. 3,994,469 shares of the company’s stock traded hands. GlaxoSmithKline plc has a one year low of $47.51 and a one year high of $56.73. The stock’s 50-day moving average is $52.67 and its 200-day moving average is $53.84. The company has a market cap of $116.6 billion and a price-to-earnings ratio of 14.67.

GlaxoSmithKline plc (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $0.65 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.71 by $0.06. Analysts expect that GlaxoSmithKline plc will post $3.34 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Thursday, October 2nd. Stockholders of record on Friday, August 8th will be paid a dividend of $0.6482 per share. This represents a $2.59 annualized dividend and a dividend yield of 5.34%. The ex-dividend date is Wednesday, August 6th.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.